Literature DB >> 12743424

Colonic tumor CEA, CSAp and MUC-1 expression following radioimmunotherapy or chemotherapy.

D E Modrak1, D V Gold, D M Goldenberg, R D Blumenthal.   

Abstract

Understanding the changes in tumor biology following cytotoxic therapy may lead to a better understanding of the properties of surviving tumor cell populations and to an improved ability to target and treat these cells. This report addressed the time-dependent dynamic alterations in the expression of three tumor-associated antigens: carcinoembryonic antigen (CEA), colon-specific antigen (CSAp) and mucin-1 (MUC-1) following chemotherapy with 5-fluorouracil (5-FU) or radioimmunotherapy (RAIT; (131)I-labeled anti-CEA IgG) in human colonic tumor xenografts. Immunoassay results show that CEA and MUC-1 expression all increase rapidly after either 5-FU or RAIT. GW-39 tumors show a 2.7-fold increase in CEA expression after a maximum tolerated dose of RAIT, being highest after 21 days, while LS174T and HT-29 tumors maximally increase expression 8.3- and 2.6-fold on day 7 after RAIT, respectively. The change in LS174T is short-term, whereas the change in HT-29 is maintained for at least 4 weeks. Serum CEA levels in these tumor- bearing mice also increase in parallel to the changes observed in tumor. MUC-1 increases 2.5-fold by day 5-7 following RAIT in LS174T tumors and 6-fold by day 14 following RAIT in GW-39 tumors, with a corresponding increase in serum MUC-1. Dramatic increases in CSAp after RAIT were also demonstrated in GW-39 tissue by immunohistochemistry. Thus, these data indicate that the response of tumor cells to low-dose-rate radiation from RAIT or to chemotherapy is associated with an increase of CEA, MUC-1 and CSAp. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12743424     DOI: 10.1159/000070658

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  14 in total

1.  Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing.

Authors:  Sofia R Gameiro; Jorge A Caballero; James W Hodge
Journal:  Cancer Biother Radiopharm       Date:  2012-02-08       Impact factor: 3.099

2.  DNA damage signaling is activated during cancer progression in human colorectal carcinoma.

Authors:  Kazuhito Oka; Toshiki Tanaka; Tadahiko Enoki; Koichi Yoshimura; Mako Ohshima; Masayuki Kubo; Tomoyuki Murakami; Toshikazu Gondou; Yoshihide Minami; Yoshihiro Takemoto; Eijirou Harada; Takaaki Tsushimi; Tao-Sheng Li; Frank Traganos; Zbigniew Darzynkiewicz; Kimikazu Hamano
Journal:  Cancer Biol Ther       Date:  2010-02-25       Impact factor: 4.742

Review 3.  What role do mucins have in the development of laryngeal squamous cell carcinoma? A systematic review.

Authors:  Fabian Sipaul; Martin Birchall; Anthony Corfield
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-04-28       Impact factor: 2.503

Review 4.  Chemotherapy and Physical Therapeutics Modulate Antigens on Cancer Cells.

Authors:  Wojciech Szlasa; Natalia Janicka; Natalia Sauer; Olga Michel; Bernadetta Nowak; Jolanta Saczko; Julita Kulbacka
Journal:  Front Immunol       Date:  2022-07-06       Impact factor: 8.786

5.  Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria.

Authors:  Chetan Bettegowda; Long H Dang; Ross Abrams; David L Huso; Larry Dillehay; Ian Cheong; Nishant Agrawal; Scott Borzillary; J Michael McCaffery; E Latice Watson; Kuo-Shyan Lin; Fred Bunz; Kwamena Baidoo; Martin G Pomper; Kenneth W Kinzler; Bert Vogelstein; Shibin Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

6.  The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing.

Authors:  Mala Chakraborty; Elizabeth K Wansley; Jorge A Carrasquillo; Sarah Yu; Chang H Paik; Kevin Camphausen; Michael D Becker; William F Goeckeler; Jeffrey Schlom; James W Hodge
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

7.  Antitumor efficacy of colon-specific HPMA copolymer/9-aminocamptothecin conjugates in mice bearing human-colon carcinoma xenografts.

Authors:  Song-Qi Gao; Yongen Sun; Pavla Kopecková; C Matthew Peterson; Jindrich Kopecek
Journal:  Macromol Biosci       Date:  2009-11-10       Impact factor: 4.979

8.  Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis.

Authors:  Alexander Gelbard; Charlie T Garnett; Scott I Abrams; Vyomesh Patel; J Silvio Gutkind; Claudia Palena; Kwong-Yok Tsang; Jeffrey Schlom; James W Hodge
Journal:  Clin Cancer Res       Date:  2006-03-15       Impact factor: 12.531

9.  A pan inhibitor of DASH family enzymes induces immunogenic modulation and sensitizes murine and human carcinoma cells to antigen-specific cytotoxic T lymphocyte killing: implications for combination therapy with cancer vaccines.

Authors:  Renee N Donahue; Brynn B Duncan; Terry J Fry; Barry Jones; William W Bachovchin; Christopher P Kiritsy; Jack H Lai; Wengen Wu; Peng Zhao; Yuxin Liu; Kwong-Yok Tsang; James W Hodge
Journal:  Vaccine       Date:  2014-04-13       Impact factor: 3.641

10.  In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer.

Authors:  Anna R Kwilas; Renee N Donahue; Michael B Bernstein; James W Hodge
Journal:  Front Oncol       Date:  2012-09-06       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.